Form 8-K SCICLONE PHARMACEUTICALS For: May 11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Wall St gains as AI earnings lift tech, inflation data supports rate-hold bets
- Oil prices dip as investors weigh lower demand forecasts against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Wall Street ends down as US-Iran peace optimism fades
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
SciClone Pharma (SCLN) Tops Q1 EPS by 16c
May 11, 2015 4:43 PM EDTSciClone Pharma (NASDAQ: SCLN) reported Q1 EPS of $0.19, $0.16 better than the analyst estimate of $0.03. Revenue for the quarter came in at $33.6 million versus the consensus estimate of $34 million.
As of March 31, 2015, cash, cash equivalents and short-term investments totaled $96.1 million, compared to $86.3 million as of... More
